AbCellera Biologics (ABCL) Return on Sales (2020 - 2024)
AbCellera Biologics (ABCL) has disclosed Return on Sales for 5 consecutive years, with 5.14% as the latest value for Q3 2024.
- For the quarter ending Q3 2024, Return on Sales fell 80.0% year-over-year to 5.14%, compared with a TTM value of 5.14% through Sep 2024, down 257.0%, and an annual FY2024 reading of 5.65%, down 180.0% over the prior year.
- Return on Sales was 5.14% for Q3 2024 at AbCellera Biologics, down from 4.8% in the prior quarter.
- Across five years, Return on Sales topped out at 0.78% in Q4 2020 and bottomed at 5.14% in Q4 2023.
- Average Return on Sales over 5 years is 1.73%, with a median of 0.45% recorded in 2020.
- The sharpest move saw Return on Sales surged 414bps in 2022, then tumbled -460bps in 2023.
- Year by year, Return on Sales stood at 0.78% in 2020, then tumbled by -44bps to 0.43% in 2021, then crashed by -422bps to 1.39% in 2022, then crashed by -270bps to 5.14% in 2023, then changed by 0bps to 5.14% in 2024.
- Business Quant data shows Return on Sales for ABCL at 5.14% in Q3 2024, 4.8% in Q2 2024, and 4.11% in Q1 2024.